EE418 Cost-Effectiveness Analysis of Halobetasol and Tazarotene (DUOBRIITM) Compared to Standard of Care for Adult Patients with Moderate-to-Severe Plaque Psoriasis in Québec
Jun 1, 2023, 00:00
10.1016/j.jval.2023.03.719
https://www.valueinhealthjournal.com/article/S1098-3015(23)00819-7/fulltext
Title :
EE418 Cost-Effectiveness Analysis of Halobetasol and Tazarotene (DUOBRIITM) Compared to Standard of Care for Adult Patients with Moderate-to-Severe Plaque Psoriasis in Québec
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(23)00819-7&doi=10.1016/j.jval.2023.03.719
First page :
Section Title :
Open access? :
No
Section Order :
10197